

Grazia Pennisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2163951/publications.pdf>

Version: 2024-02-01

16
papers

566
citations

1040056

9
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

1027
citing authors

#	ARTICLE	IF	CITATIONS
1	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 1032-1044.	4.3	6
2	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	3.9	4
3	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	4.4	90
4	<i>PCSK9</i> rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021, 41, 321-332.	3.9	26
5	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 160, 1634-1646.e7.	1.3	82
6	Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C. <i>Minerva Gastroenterology</i> , 2021, 67, 254-263.	0.5	2
7	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2389-2396.	2.8	6
8	<i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.	3.9	6
9	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1979-1981.	4.4	10
10	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
11	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.	4.4	102
12	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938.	1.9	3
13	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
14	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4334.	2.6	21
15	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	4.4	66
16	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018, 11, 121.	3.8	41